Matches in Nanopublications for { ?s ?p "[While SNP309G enhances Sp1 transcription factor binding and MDM2 transcription, SNP285C antagonizes Sp1 binding and reduces the risk of breast-, ovary- and endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 12 of
12
with 100 items per page.
- assertion description "[While SNP309G enhances Sp1 transcription factor binding and MDM2 transcription, SNP285C antagonizes Sp1 binding and reduces the risk of breast-, ovary- and endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[While SNP309G enhances Sp1 transcription factor binding and MDM2 transcription, SNP285C antagonizes Sp1 binding and reduces the risk of breast-, ovary- and endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[While SNP309G enhances Sp1 transcription factor binding and MDM2 transcription, SNP285C antagonizes Sp1 binding and reduces the risk of breast-, ovary- and endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[While SNP309G enhances Sp1 transcription factor binding and MDM2 transcription, SNP285C antagonizes Sp1 binding and reduces the risk of breast-, ovary- and endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[While SNP309G enhances Sp1 transcription factor binding and MDM2 transcription, SNP285C antagonizes Sp1 binding and reduces the risk of breast-, ovary- and endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[While SNP309G enhances Sp1 transcription factor binding and MDM2 transcription, SNP285C antagonizes Sp1 binding and reduces the risk of breast-, ovary- and endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1230557.RAChZczoGcjf_og7yGmm0jMzbvBWd6J3AANhyUGDV4zUs130_assertion description "[While SNP309G enhances Sp1 transcription factor binding and MDM2 transcription, SNP285C antagonizes Sp1 binding and reduces the risk of breast-, ovary- and endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1230557.RAChZczoGcjf_og7yGmm0jMzbvBWd6J3AANhyUGDV4zUs130_provenance.
- NP1230552.RAYAI5bEv--so3KtN3lPmpuov6cI9Ndgm6YuvwqGGmKVs130_assertion description "[While SNP309G enhances Sp1 transcription factor binding and MDM2 transcription, SNP285C antagonizes Sp1 binding and reduces the risk of breast-, ovary- and endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1230552.RAYAI5bEv--so3KtN3lPmpuov6cI9Ndgm6YuvwqGGmKVs130_provenance.
- NP1230553.RAQk3fskB3zBpz_HWRfET--URX2GsshgeT9qWrP02b36M130_assertion description "[While SNP309G enhances Sp1 transcription factor binding and MDM2 transcription, SNP285C antagonizes Sp1 binding and reduces the risk of breast-, ovary- and endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1230553.RAQk3fskB3zBpz_HWRfET--URX2GsshgeT9qWrP02b36M130_provenance.
- NP1230554.RAjLebRSDYFqhKyqsahAKFc3efdsAk16Gic4q3LgN6bBQ130_assertion description "[While SNP309G enhances Sp1 transcription factor binding and MDM2 transcription, SNP285C antagonizes Sp1 binding and reduces the risk of breast-, ovary- and endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1230554.RAjLebRSDYFqhKyqsahAKFc3efdsAk16Gic4q3LgN6bBQ130_provenance.
- NP1230555.RALyCSvN2TDfKw1y9iYwfRtEYLlnYfQMa2-bAZpEhbbF8130_assertion description "[While SNP309G enhances Sp1 transcription factor binding and MDM2 transcription, SNP285C antagonizes Sp1 binding and reduces the risk of breast-, ovary- and endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1230555.RALyCSvN2TDfKw1y9iYwfRtEYLlnYfQMa2-bAZpEhbbF8130_provenance.
- NP1230556.RA5e0fYKH1jY896mOdBczPOA9fM8b2qw6jNQ5zQ3nexLs130_assertion description "[While SNP309G enhances Sp1 transcription factor binding and MDM2 transcription, SNP285C antagonizes Sp1 binding and reduces the risk of breast-, ovary- and endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1230556.RA5e0fYKH1jY896mOdBczPOA9fM8b2qw6jNQ5zQ3nexLs130_provenance.